LONG ACTING ERYTHROPOIETINS THAT MAINTAIN TISSUE PROTECTIVE ACTIVITY OF ENDOGENOUS ERYTHROPOIETIN

WIPO Patent Application WO2004022577

A3

Methods for increasing the hematocrit of an individual while maintaining the tissue protective activities of endogenous through the administration of a pharmaceutical compound containing chemically modified long acting erythropoietin. Also disclosed are the new chemically modified long acting erythropoietins, methods of producing the chemically modified long acting erythropoietins, and compositions comprising the chemically modified long acting erythropoietins.

CERAMI ANTHONY (US)
SMART JOHN (US)
BRINES MICHAEL (US)
CERAMI CARLA (US)

PCT/US2003/028073

September 16, 2004

September 09, 2003

Click for automatic bibliography generation  

WARREN PHARMACEUTICALS INC (US)
CERAMI ANTHONY (US)
SMART JOHN (US)
BRINES MICHAEL (US)
CERAMI CARLA (US)
KENNETH S WARREN INST INC (US)

A61K38/18; A61K47/48; C07K14/505; (IPC1-7): A61K38/18; A61K38/16; A61K38/22; C07K1/10; C07K14/505

US6340742B1

2002-01-22

EGRIE ET AL: "Development and Characterization of novel erythropoiesis stimulating protein (NESP)", NEPHROL. DIAL. TRANSPLANT, vol. 16, no. SUPPLEMENT 3, 2001, pages 3 - 13, XP001059695
HANSEN ET AL: "A randomized, blinded, placebo-controlled, phase II, dose finding study of ARANESP in patients with lymphoproliferative malignancies", BLOOD, vol. 96, no. 11, November 2000 (2000-11-01), pages 155B, XP002978246
VANSTEENKISTE ET AL: "Darbepoetin alfa: a new approach to the treatment of chemotherapy-induced anaemia", EXPERT. OPIN. BIOL. THER., vol. 3, no. 3, 2003, pages 501 - 508, XP002978255

View/Download PDF      PDF Help

Previous Patent: SHORT PEPTIDES FROM THE '2ND LOOP' OF 7 TRANSMEMBRANE RECEPTOR WHICH SELECTIVELY MODULATE SIGNAL TRA...

Next Patent: METHODS, COMPOSITIONS AND LIBRARIES PERTAINING PNA DIMER AND PNA OLIGOMER SYNTHESIS